It's been less than three months since Warren Buffett stunned Berkshire Hathaway
He was quick to play down the diagnosis, and rightfully so. It was detected early, and Buffett claims that it's not life-threatening. Cancer is ugly, and most of us have lost loved ones to the disease, but medical advances in both detecting and treating it make this a winnable war in many cases.
Unfortunately, it doesn't always play out that way.
A few hours after Tellabs' announcement, security software specialist Sourcefire
Two tech CEOs in colon-cancer-related announcements in the same day is an unfortunate coincidence, but it's also likely to draw attention to Buffett's situation. Yes, it's prostate cancer. Yes, it was caught early. However, investors can't be reminded enough about Buffett's mortality.
He turns 82 next month. No one lasts forever, even someone as zestful and with as cheery a disposition as Buffett. It also doesn't help that Berkshire Hathaway's investments in recent years haven't been as successful as Buffett's calls earlier in his career.
Buffett claims to have already chosen a successor -- and two backups -- though the actual names haven't been made public. As more cancer stories creep up, you can be sure that attention will turn back to Buffett. In the end, though, cancer may not be as life-threatening as time itself for Buffett. We all need to go sometime, and the greatest investor of our generation knows that.
The Motley Fool owns shares of Berkshire Hathaway. Motley Fool newsletter services have recommended buying shares of Berkshire Hathaway and Sourcefire. The Motley Fool has a disclosure policy. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.
Longtime Fool contributor Rick Munarriz calls them as he sees them. He does not own shares in any of the stocks in this story. Rick is also part of the Rule Breakers newsletter research team, seeking out tomorrow's ultimate growth stocks a day early.